What are the advantages of eculizumab over plasma exchange in the treatment of pediatric atypical hemolytic uremic syndrome (aHUS)?

Updated: Nov 12, 2018
  • Author: Robert S Gillespie, MD, MPH; Chief Editor: Craig B Langman, MD  more...
  • Print

Eculizumab is the treatment of choice for patients with aHUS. [29, 30] Its advantages over plasma exchange include the following:

  • Efficacy proven in controlled clinical trials

  • FDA approval for indication of aHUS

  • Simple intravenous administration

  • No requirement for specialized equipment and specially trained personnel

  • No need for donor plasma products

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!